G1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2019 Earnings Conference Call - Final Transcript
Nov 05, 2019 • 04:30 pm ET
Good afternoon, ladies and gentlemen, and welcome to the G1 Therapeutics' Third Quarter 2019 Financial Results Conference Call. [Operator Instructions]
I would now like to turn the conference over to your host, Mr. Jeff Macdonald, Head of Investor Relations for G1 Therapeutics. Please go ahead, sir.
Thank you, operator. Good afternoon, everyone and welcome to the G1 Therapeutics third Quarter 2019 corporate and financial update. Joining me are Mark Velleca, Chief Executive Officer; Raj Malik, Chief Medical Officer and Senior Vice President, R&D; and Jen Moses, Chief Financial Officer.
Before we begin, I would like to remind you that this call will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from expected results. Please refer to our filings with the SEC, which are available on the SEC website or our corporate website for information concerning risk factors that could affect the Company.
I'll now turn the call over to Mark.
Thanks, Jeff. Good afternoon, everyone and thank you for joining us. On today's call, we'll review our progress in the third quarter and provide an update on upcoming clinical and regulatory milestones expected this year and next. These milestones provide a foundation for the successful launch of our first commercial product, trilaciclib and position lerociclib and G1T48 as important new treatment options for people living with breast cancer.
Raj will discuss data on trilaciclib and G1T48 that were presented in September at the European Society for Medical Oncology meeting or ESMO. He will also preview data on lerociclib being presented at the San Antonio Breast Cancer Symposium in December. Following Raj's comments, Jen will review the financials for quarter. Then we'll open the call for questions.
I'll begin with trilaciclib. Based on advisory board feedback, meetings with key opinion leaders and quantitative market research with healthcare professionals, we believe that trilaciclib can usher in a new standard of care that will benefit cancer patients, who received the most frequently administered chemotherapy regimens. Every year hundreds of thousands of patients experience both the benefits and negative consequences of chemotherapy. While chemo is a cornerstone of effective cancer treatment, it does not differentiate between healthy and cancer cells, showing both, including important stem cells in the bone marrow that produce white blood cells, red blood cells and platelets.
This chemotherapy induced bone marrow damage is known as myelosuppression. When white cells, red cells and platelets become depleted, patients receiving chemotherapy are at an increased risk of infection, experience anemia and fatigue and are at an increased risk of bleeding. Myelosuppression can impair a patient's ability to complete the full course of chemotherapy on schedule and often requires the administration of rescue interventions such as growth factors and blood transfusions. Patients, oncologists, and payers recognize the need to improve on what has become accepted as the unavoidable downside of chemotherapy.
Trilaciclib is positioned to address this need, making chemotherapy safer, reducing side effects,